Equinix, Inc. (LON:0II4)

Theseus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Property, Plant & Equipment	22,688	20,668	20,050	18,077	16,728	15,978
Cash & Equivalents	3,660	3,081	2,096	1,906	1,536	1,605
Accounts Receivable	1,221	1,051	1,056	882.99	747.2	690.27
Other Receivables	-	329	247	232.11	187.35	169.95
Investment In Debt and Equity Securities	-	-	-	-	-	4.53
Goodwill	5,982	5,504	5,737	5,654	5,372	5,473
Other Intangible Assets	1,389	1,417	1,705	1,898	1,935	2,171
Restricted Cash	5	1	-	1.7	12.19	11.14
Other Current Assets	1,664	985	169	282.03	474.01	128.4
Deferred Long-Term Tax Assets	-	48	62	44.63	59.82	66.42
Deferred Long-Term Charges	3	554	533	462.36	373.64	272.24
Other Long-Term Assets	2,237	1,447	996	869.15	492.61	437.38
Total Assets	38,849	35,085	32,651	30,311	27,919	27,007
Current Portion of Long-Term Debt	1,913	1,204	1,006	9.85	33.09	232.48
Current Portion of Leases	369	333	269	290.96	291.87	291.89
Long-Term Debt	16,022	14,007	12,725	12,752	11,571	10,306
Long-Term Leases	3,547	3,417	3,454	3,417	3,097	3,093
Accounts Payable	1,213	133	162	115.95	84.08	77.71
Accrued Expenses	-	951	944	833.65	743.76	707.36
Current Income Taxes Payable	-	109	81	55.2	51.3	59.8
Current Unearned Revenue	-	123	125	132.09	109.74	101.26
Other Current Liabilities	746	496	575	400.6	292.12	554.27
Long-Term Unearned Revenue	-	150	154	155.33	87.5	71.24
Long-Term Deferred Tax Liabilities	-	339	394	383.36	340.29	290.37
Other Long-Term Liabilities	932	271	248	259.17	335.63	587.39
Total Liabilities	24,742	21,533	20,137	18,805	17,037	16,373
Common Stock	-	-	-	0.09	0.09	0.09
Additional Paid-In Capital	21,324	20,895	18,596	17,320	15,985	15,028
Distributions in Excess of Earnings	-5,811	-5,593	-4,761	-4,353	-3,905	-3,359
Treasury Stock	-30	-39	-56	-71.97	-112.21	-122.12
Comprehensive Income & Other	-1,399	-1,735	-1,290	-1,389	-1,086	-913.37
Total Common Equity	14,084	13,528	12,489	11,506	10,882	10,634
Minority Interest	23	24	25	-0.13	-0.32	0.13
Shareholders' Equity	14,107	13,552	12,514	11,506	10,882	10,634
Total Liabilities & Equity	38,849	35,085	32,651	30,311	27,919	27,007
Total Debt	21,851	18,961	17,454	16,470	14,993	13,923
Net Cash (Debt)	-18,191	-15,880	-15,358	-14,563	-13,456	-12,318
Net Cash Per Share	-187.09	-165.72	-163.37	-158.59	-148.84	-139.33
Filing Date Shares Outstanding	97.86	97.33	94.62	92.74	90.72	89.29
Total Common Shares Outstanding	97.87	97.29	94.48	92.62	90.57	89.13
Book Value Per Share	143.91	139.05	132.19	124.23	120.15	119.30
Tangible Book Value	6,713	6,607	5,047	3,954	3,575	2,990
Tangible Book Value Per Share	68.59	67.91	53.42	42.69	39.47	33.55
Land	-	1,652	1,407	1,253	970.98	944.09
Buildings	-	9,475	8,972	8,014	7,382	6,557
Construction In Progress	-	2,204	1,918	1,195	967.56	1,364

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.